Paul Schulwitz

170020 Access DB#

SEARCH REQUEST FORM

RECEIVED

Scientific and Technical Information Center

OCT 31 200

11-07-01

Requester's Full Name: Rebecca Look Examiner #: 69826 Date: 10/31/05

Art Unit: 1614 Phone Number 30(5)-[illegible] Serial Number: 10/628,141

Mail Box and Bldg/Room Location: 3 C70 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of invention: ~~All attached~~

Inventors (please provide full names): ~~All attached~~

Earliest Priority Filing Date: ✓

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please provide structures for

(a) milnacipran
(b) sibutramine
(c) bicifadine
(d) Ueplataxine
(e) duloxetine & search them

1. to treat depression
2. to " atypical depression 2° to pain. (DSP)

- how is DSP defined + is is considered non-responsive to usual tx for depression (e.g. tricyclics).

Thank you
Rebecca

Deep learn!

- what other compounds are known to be dual norep. serot. reuptake inhib.
- " " " " " " are likely known to tx depression/DSP " triple reuptake inhib.

****

STAFF USE ONLY

Searcher: _____

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: _____

Date Completed: _____

Searcher Prep & Review Time: _____

Clerical Prep Time: _____

Online Time: _____

Type of Search

NA Sequence (#) _____

AA Sequence (#) _____

Structure (#) _____

Bibliographic _____

Litigation _____

Fulltext _____

Patent Family _____

Other _____

Vendors and cost where applicable

STN _____

Dialog _____

Questel/Orbit _____

Dr.Link _____

Lexis/Nexis _____

Sequence Systems _____

WWW/Internet _____

Other (specify) _____

Application

L3 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:142815 HCAPLUS
DOCUMENT NUMBER: 140:157480
ENTRY DATE: Entered STN: 22 Feb 2004
TITLE: Monoamine reuptake inhibitors for the treatment and prevention of depression secondary to pain
INVENTOR(S): Rao, Srinivas G.; Kranzler, Jay D.
PATENT ASSIGNEE(S): Cypress Bioscience, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 28,547.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
INT. PATENT CLASSIF.:
MAIN: A61K031-165
US PATENT CLASSIF.: 514619000
CLASSIFICATION: 1-11 (Pharmacology)
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 2004034101	A1	20040219	US 2003-628141	20030724	<--
US 2003139476	A1	20030724	US 2001-14149	20011105	
US 6635675	B2	20031021			
US 2003130353	A1	20030710	US 2001-28547	20011219	
US 6602911	B2	20030805			

PRIORITY APPLN. INFO.:	US 2001-14149	A2	20011105
	US 2001-28547	A2	20011219
	US 2002-398676P	P	20020724
	US 2003-443035P	P	20030128

PATENT CLASSIFICATION CODES:

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 2004034101	ICM	A61K031-165	
	INCL	514619000	
US 2004034101	NCL	514/619.000	
	ECLA	A61K031/00; A61K031/131+M; A61K031/135+M; A61K031/165; A61K031/165+M	<--
US 2003139476	NCL	514/620.000	
	ECLA	A61K031/00; A61K031/165	
US 2003130353	NCL	514/620.000	
	ECLA	A61K031/00; A61K031/135+M; A61K031/165; A61K031/165+M	

ABSTRACT:
Methods for the prevention or treatment of a typical depression secondary to pain (DSP) have been developed. The method generally involves administering an effective amount of a monoamine reuptake inhibitor to treat or prevent symptoms of DSP. In a preferred embodiment, a therapeutically effective amount of a dual serotonin/norepinephrine reuptake inhibitor (SNRI) compound of a specific type, or a pharmaceutically acceptable salt thereof, is administered. The most preferred SNRI compds. are non-tricyclic SNRIs, wherein serotonin reuptake inhibition is greater than norepinephrine reuptake inhibition; and NSRIs, wherein norepinephrine reuptake inhibition is greater than serotonin reuptake inhibition. The most preferred compound is milnacipran, or a bioequivalent or pharmaceutically acceptable salt thereof. Other preferred compds. are duloxetine and venlafaxine or a bioequivalent or pharmaceutically acceptable salt thereof. In yet another embodiment, a therapeutically effective amount of a non-tricyclic triple reuptake inhibitor (TRI) compound of a specific type, or a

pharmaceutically acceptable salt thereof, is administered. The TRI compds. are characterized by their ability to block the reuptake (and hence increase central concns. of) the three primary brain monoamines: serotonin, noradrenaline, and dopamine.

SUPPL. TERM: monoamine reuptake inhibitor depression secondary to pain; milnacipran duloxetine venlafaxine depression secondary to pain

INDEX TERM: Glutamate antagonists
(NMDA antagonists; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Pain
(abdominal; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Disease, animal
(back pain, lower back; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Body, anatomical
(back, disease, pain, lower back; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Pain
(back, lower back; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Disease, animal
(chronic pain from; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Pain
(chronic; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Mental disorder
(depression; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Head
(face, myofascial face pain; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: 5-HT reuptake inhibitors
Analgesics
Antidepressants
Drug delivery systems
Headache
Human
Pain
(monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Emotion
(mood reactivity; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Nerve, disease
(neuropathy, neuropathic pain; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Nervous system
(neurovegetative symptoms; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Abdomen, disease
Neck, anatomical

(pain; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Body, anatomical
(pelvis, pelvic pain; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Biological transport
(reuptake; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Seizures
(risk; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Thorax
(typical chest pain; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: **50-67-9**, Serotonin, biological studies
ROLE: BSU (Biological study, unclassified); BIOL (Biological study)
(monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: **765-30-0D**, Aminocyclopropane, derivs.
92623-85-3, Milnacipran **106650-56-0**, Sibutramine
ROLE: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: **51-41-2**, Norepinephrine **51-61-6**, Dopamine, biological studies
ROLE: BSU (Biological study, unclassified); BIOL (Biological study)
(reuptake inhibitors; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

IT **50-67-9**, Serotonin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

RN 50-67-9 HCAPLUS

CN 1H-Indol-5-ol, 3-(2-aminoethyl)- (9CI) (CA INDEX NAME)



IT **765-30-0D**, Aminocyclopropane, derivs. **92623-85-3**, Milnacipran **106650-56-0**, Sibutramine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

RN 765-30-0 HCAPLUS

CN Cyclopropanamine (9CI) (CA INDEX NAME)



RN 92623-85-3 HCAPLUS
CN Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 106650-56-0 HCAPLUS
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)- (9CI) (CA INDEX NAME)



IT **51-41-2**, Norepinephrine **51-61-6**, Dopamine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(reuptake inhibitors; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)
RN 51-41-2 HCAPLUS
CN 1,2-Benzenediol, 4-[(1R)-2-amino-1-hydroxyethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 51-61-6 HCAPLUS
CN 1,2-Benzenediol, 4-(2-aminoethyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:532350 HCAPLUS
DOCUMENT NUMBER: 139:63355
ENTRY DATE: Entered STN: 11 Jul 2003
TITLE: Methods using a dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain
INVENTOR(S): Kranzler, Jay D.; Rao, Srinivas G.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Ser. No. 14,149.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
INT. PATENT CLASSIF.:
MAIN: A61K031-5513
SECONDARY: A61K031-496; A61K031-485; A61K031-55; A61K031-198; A61K031-165; A61K031-137
US PATENT CLASSIF.: 514620000; 514217000; 514221000; 514253040; 514282000; 514649000; 514561000; 514567000
CLASSIFICATION: 1-11 (Pharmacology)
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003130353	A1	20030710	US 2001-28547	20011219
US 6602911	B2	20030805		
US 2003139476	A1	20030724	US 2001-14149	20011105
US 6635675	B2	20031021		
WO 2003053426	A1	20030703	WO 2002-US40976	20021219
W: CA, US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
US 2004019116	A1	20040129	US 2003-623431	20030718
US 2004229956	A1	20041118	US 2003-623378	20030718
US 2004034101	A1	20040219	US 2003-628141	20030724 <--

PRIORITY APPLN. INFO.:

US 2001-14149	A2	20011105
US 2001-28547	A1	20011219
US 2002-398676P	P	20020724
US 2003-443035P	P	20030128

PATENT CLASSIFICATION CODES:

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003130353	ICM	A61K031-5513
	ICS	A61K031-496; A61K031-485; A61K031-55; A61K031-198; A61K031-165; A61K031-137
	INCL	514620000; 514217000; 514221000; 514253040; 514282000; 514649000; 514561000; 514567000
US 2003130353	NCL	514/620.000

	ECLA	A61K031/00; A61K031/135+M; A61K031/165; A61K031/165+M
US 2003139476	NCL	514/620.000
	ECLA	A61K031/00; A61K031/165
WO 2003053426	ECLA	A61K031/00; A61K031/135+M; A61K031/165; A61K031/165+M
US 2004019116	NCL	514/620.000
	ECLA	A61K031/00; A61K031/135+M; A61K031/165; A61K031/165+M
US 2004229956	NCL	514/619.000
	ECLA	A61K031/00; A61K031/135+M; A61K031/165; A61K031/165+M
US 2004034101	NCL	514/619.000
	ECLA	A61K031/00; A61K031/131+M; A61K031/135+M; A61K031/165; A61K031/165+M <--

ABSTRACT:
The invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin-norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein the dual serotonin-norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.

SUPPL. TERM: pain treatment dual serotonin norepinephrine reuptake inhibitor; fibromyalgia syndrome treatment dual serotonin norepinephrine reuptake inhibitor; chronic fatigue syndrome treatment dual serotonin norepinephrine reuptake inhibitor; milnacipran pain fibromyalgia chronic fatigue syndrome

INDEX TERM: Fatigue, biological
(chronic fatigue syndrome; dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain)

INDEX TERM: 5-HT reuptake inhibitors
Analgesics
Biological transport
Human
Pain
(dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain)

INDEX TERM: Anticonvulsants
Antidepressants
Appetite depressants
Hypnotics and Sedatives
Muscle relaxants
Nervous system stimulants
(dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain, and use with other agents)

INDEX TERM: Muscle, disease
(fibromyalgia; dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain)

INDEX TERM: Drug delivery systems
(sustained-release; dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain)

INDEX TERM: Drug delivery systems
(unit doses; dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain)

INDEX TERM: **50-67-9**, Serotonin, biological studies
51-41-2, Norepinephrine
ROLE: BSU (Biological study, unclassified); BIOL (Biological study)
(dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain)

INDEX TERM: **92623-85-3**, Milnacipran
ROLE: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain)

INDEX TERM: **57-27-2**, Morphine, biological studies **59-92-7**, biological studies **76-57-3**, Codeine **298-46-4**, Carbamazepine **300-62-9**, Amphetamine **439-14-5**, Valium **4205-90-7**, Clonidine **19794-93-5**, Trazodone **27203-92-5**, Tramadol **51322-75-9**, Tizanidine **60142-96-3**, Neurontin **104632-26-0**, Pramipexole **106650-56-0**, Sibutramine **148553-50-8**, Pregabalin
ROLE: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain, and use with other agents)

IT **50-67-9**, Serotonin, biological studies **51-41-2**, Norepinephrine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain)

RN 50-67-9 HCAPLUS
CN 1H-Indol-5-ol, 3-(2-aminoethyl)- (9CI) (CA INDEX NAME)



RN 51-41-2 HCAPLUS
CN 1,2-Benzenediol, 4-[(1R)-2-amino-1-hydroxyethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **92623-85-3**, Milnacipran

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain)
RN 92623-85-3 HCAPLUS
CN Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **57-27-2**, Morphine, biological studies **59-92-7**, biological studies **76-57-3**, Codeine **298-46-4**, Carbamazepine **300-62-9**, Amphetamine **439-14-5**, Valium **4205-90-7**, Clonidine **19794-93-5**, Trazodone **27203-92-5**, Tramadol **51322-75-9**, Tizanidine **60142-96-3**, Neurontin **104632-26-0**, Pramipexole **106650-56-0**, Sibutramine **148553-50-8**, Pregabalin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain, and use with other agents)
RN 57-27-2 HCAPLUS
CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 59-92-7 HCAPLUS
CN L-Tyrosine, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 76-57-3 HCAPLUS
CN Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 298-46-4 HCAPLUS
CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 300-62-9 HCAPLUS
CN Benzeneethanamine, α-methyl- (9CI) (CA INDEX NAME)



RN 439-14-5 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl- (8CI, 9CI) (CA INDEX NAME)



RN 4205-90-7 HCAPLUS
CN 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 19794-93-5 HCAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 27203-92-5 HCAPLUS
CN Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 51322-75-9 HCAPLUS
CN 2,1,3-Benzothiadiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 60142-96-3 HCAPLUS

CN Cyclohexaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 104632-26-0 HCAPLUS
CN 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 106650-56-0 HCAPLUS
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 148553-50-8 HCAPLUS
CN Hexanoic acid, 3-(aminomethyl)-5-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 92623-85-3 REGISTRY
ED Entered STN: 17 Dec 1984
CN Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, (1R,2S)-rel- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, cis-(±)-
OTHER NAMES:
CN (±)-Milnacipran
CN (1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
CN Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, cis-
CN Midalcipran
CN **Milnacipran**
CN Toledomin
FS STEREOSEARCH
DR 105310-09-6
MF C15 H22 N2 O
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CIN, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

248 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
249 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 106650-56-0 REGISTRY
ED Entered STN: 14 Feb 1987
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Medaria
CN Meridia
CN **Sibutramine**
FS 3D CONCORD
MF C17 H26 Cl N
CI COM
SR World Health Organization (WHO)
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IMSCOSEARCH, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

455 REFERENCES IN FILE CA (1907 TO DATE)
30 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
456 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 71195-57-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN 3-Azabicyclo[3.1.0]hexane, 1-(4-methylphenyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3-Azabicyclo[3.1.0]hexane, 1-(4-methylphenyl)-, (±)-
OTHER NAMES:
CN **Bicifadine**
DR 86215-52-3
MF C12 H15 N
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CIN, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, MEDLINE, PHAR, PROMT, SYNTHLINE, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10 REFERENCES IN FILE CA (1907 TO DATE)
10 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 93413-69-5 REGISTRY
ED Entered STN: 18 Dec 1984
CN Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, (±)-
OTHER NAMES:
CN (±)-Venlafaxine
CN Venlafaxin
CN **Venlafaxine**
CN Venlafexine
DR 131801-71-3
MF C17 H27 N O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

940 REFERENCES IN FILE CA (1907 TO DATE)
16 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
946 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 116539-59-4 REGISTRY
ED Entered STN: 25 Sep 1988
CN 2-Thiophenepropanamine, N-methyl-γ-(1-naphthalenyloxy)-, (γS)-
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Thiophenepropanamine, N-methyl-γ-(1-naphthalenyloxy)-, (S)-
OTHER NAMES:
CN (S)-Duloxetine
CN **Duloxetine**
CN LY 248686
FS STEREOSEARCH
MF C18 H19 N O S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PROMT, PROUSDDR, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

254 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
257 REFERENCES IN FILE CAPLUS (1907 TO DATE)